Clinical Trials Logo
  1. Home
  2. Ovarian Cancer
  3. NCT06317610
  4. Details
NCT06317610 Clinical Trial

Artificial Intelligence Model for Growth Prediction of Ovarian Cancer Organoids

Ovarian Cancer Clinical Trial

Official title:
Development and Validation of Growth Prediction Model for Ovarian Cancer Organoids Based on Bright Field Image and Deep Learning

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06317610
Other study ID # CQGOG0206
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2022
Est. completion date May 30, 2024

Study information
Verified date March 2024
Source Chongqing University Cancer Hospital
Contact Dongling Zou, MD
Phone 13657690699
Email cqzl_zdl@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The present study aims to collect early bright field image of patient-derived organoids with ovarian cancer. By leveraging artificial intelligence, this study will seek to construct and refine algorithms that able to predict growth of ovarian cancer organoids.

Recruitment information / eligibility
Status Recruiting
Enrollment 100
Est. completion date May 30, 2024
Est. primary completion date April 30, 2024
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria: - Patients must have histologically confirmed diagnosis of epithelial ovarian cancer - Patients received biopsy or puncture to obtain tumor tissues or malignant effusion - Patients voluntarily participated in the study and signed informed consent. Exclusion Criteria: - Non-epithelial ovarian cancer - No sufficient amount of tumor tissues or malignant effusion for organoids establishment.

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• growth prediction of ovarian cancer organoids in the frame of bright field image by leveraging AI
biopsy or puncture: Patients received biopsy or puncture to obtain tumor tissues or Malignant effusion for organoids establishment

Locations
Country Name City State
China Chongqing Cancer Hospital Chongqing Chongqing

Sponsors (1)
Lead Sponsor Collaborator
Chongqing University Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary AUC of growth prediction performance using deep learning model AUC =Area under receiver operating characteristic curve up to 3 years
Primary Accuracy of growth prediction using deep learning model Accuracy=( the number of correctly classified samples)/( the number of total samples) up to 3 years
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2